Insmed Stock (INSM): Share Price, Forecast & News Guide

by VT Markets /
Nov 17, 2026
Insmed Share Price

Few stories in biotech right now are as puzzling as the one unfolding around Insmed stock. In its latest quarter, Insmed Incorporated reported total revenue of $524.4 million, a 268% jump on the same quarter a year earlier, and raised its full-year guidance for both commercial products. Yet the INSM share price is still roughly 30% lower than where it began 2026 and more than 40% below its 52-week high.

That tension between a fast-growing business and a falling share price is exactly why investors keep searching for Insmed share price updates, Insmed stock news and answers to the question is Insmed a good stock to buy. In this guide we set out the facts: the latest Insmed stock price, how the company makes money, what its quarterly results show, what analysts forecast, and the cautions worth weighing before you trade. It is evergreen, informational content, not investment advice.

Key Takeaways

  • INSM closed at $121.16 on 13 November 2026, up 2.62% on the day, with a market capitalisation of roughly $26.6 billion, which places Insmed firmly in large-cap territory.
  • The Insmed share price sits in the bottom quarter of its 52-week range of $90.39 to $212.75, and trails its level at the start of the year by around 30%, even though it has risen about 25% over the past month.
  • Q3 2026 revenue was $524.4 million, led by BRINSUPRI at $400.1 million, and management raised full-year guidance to $1.35–$1.40 billion for BRINSUPRI and $460–$470 million for ARIKAYCE.
  • The company is still loss-making (a Q3 net loss of about $100 million, or $0.46 per share), so traditional earnings multiples are not meaningful and investors tend to focus on revenue growth, pipeline progress and cash.
  • Analysts are broadly positive: an average INSM stock forecast target of about $194, within a range of $158 to $243, with roughly 24 analysts covering the shares.
  • A key catalyst is the FDA’s decision on an ARIKAYCE label expansion, with a target action date of 28 January 2027. Biotech outcomes like this can move a share price sharply in one session.

Insmed Stock Price Today: Market Snapshot

Markets were closed over the weekend, so the latest regular-session figures are from the close on Friday 13 November 2026:

MetricReading
Insmed stock price (close)$121.16
Change on the day+$3.09 (+2.62%)
Previous close$118.07
Day’s range$116.97 – $121.50
VolumeAbout 1.5 million shares (average roughly 2.8–3 million)
Market capitalisationAbout $26.6 billion
Shares outstandingAbout 219 million
52-week range$90.39 – $212.75
Five-day changeAbout +5.9%
One-month changeAbout +25%
Price-to-salesAbout 17

Different data providers round and time-stamp figures slightly differently, and an Insmed stock price today quote on your own platform may differ from the numbers above, so treat this table as a snapshot rather than a live feed. Insmed shares trade on the Nasdaq under the ticker INSM, and they pay no dividend.

Insmed Share Price: 52-Week Range and Recent Performance

Context matters for any share price, and the INSM share price is a good example. At $121.16 it is about 43% below its 52-week high of $212.75 and about 34% above its low of $90.39, which places it in the lower quarter of the range.

Why the Share Price Has Lagged Revenue Growth

Revenue and share price do not always move together, particularly in biotech. The stock opened 2026 at around $177 and has since traded as low as $90.39, even as quarterly revenue climbed from roughly $145 million in the first full quarter of BRINSUPRI’s launch to more than $520 million in Q3. Share prices reflect expectations as well as results: investors weigh trial readouts, regulatory decisions, competition, the pace of the launch and the wider mood for growth stocks. Rapid sales growth can already be priced in, and sharp moves in either direction often follow clinical or commercial updates.

Long-Term Returns Tell a Different Story

A longer view looks very different from the 2026 picture:

PeriodApproximate change in INSM
Year to date (2026)About –30%
One yearAbout –37%
Three yearsAbout +407%
Five yearsAbout +280%
Ten yearsAbout +738%

These figures, drawn from market-data providers as at 13 November 2026, show how volatile the shares can be and how much the outcome depends on the starting point. Past performance is not a guide to future results.

What Is Insmed Incorporated? Company Overview

Insmed Incorporated is a global biopharmaceutical company that develops and commercialises therapies for serious and rare diseases. It is headquartered in Bridgewater, New Jersey, and led by Chair and Chief Executive Will Lewis. Its business centres on three lead programmes:

  • BRINSUPRI (brensocatib): approved by the US FDA in August 2025 for non-cystic fibrosis bronchiectasis in patients aged 12 and over, and since approved in other major markets. In October 2026 the company launched a 25 mg tablet in Japan.
  • ARIKAYCE (amikacin liposome inhalation suspension): an established product for a type of lung disease caused by Mycobacterium avium complex (MAC), now in its ninth year on the market.
  • TPIP (treprostinil palmitil inhalation powder): a pipeline candidate in Phase 3 development for pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD), with further Phase 3 studies planned.

In August 2026 the company raised its estimate of peak annual revenue across its three lead programmes to more than $14 billion in total: more than $7 billion for BRINSUPRI, more than $6 billion for TPIP and more than $1 billion for ARIKAYCE. Peak revenue estimates are management’s own projections, not forecasts of what will happen, and they depend on successful trials, approvals and sales.

How Brensocatib Works and Why BRINSUPRI’s Market Matters

Non-cystic fibrosis bronchiectasis is a chronic lung condition in which the airways become widened and damaged, allowing mucus to build up. People living with it commonly experience a persistent cough, recurring infections and periodic flare-ups known as exacerbations. For years the treatment options were largely about managing symptoms and infections rather than targeting the inflammation behind them.

Brensocatib, the active ingredient in BRINSUPRI, is an oral tablet that inhibits an enzyme called DPP1. That enzyme helps activate neutrophil serine proteases, which are linked to the lung inflammation and tissue damage seen in this condition. It is this mechanism that investors refer to when they describe BRINSUPRI as a differentiated product, and it is also why the company is exploring brensocatib in other inflammatory conditions. The size of the patient population, the price of the treatment and the proportion of patients who start and stay on therapy are the levers that determine how large the product could become, and they are the figures worth watching in each quarterly update.

Biotech Basics: How Drug Development and FDA Approval Work

Share prices in biotech often react to regulatory steps that can seem opaque from the outside. A short primer makes the news flow easier to read, and it applies to any biotech stock, not just this one.

  • Phase 1 studies test safety and dosing in small groups.
  • Phase 2 studies look for early signs of effectiveness and refine dosing.
  • Phase 3 studies are large, confirmatory trials, usually the last step before an application for approval.
  • Regulatory review: the company submits an application, and the FDA reviews the evidence and either approves the drug, asks for more information or declines to approve it.
  • Launch: after approval, the company must win reimbursement, build prescribing habits and scale manufacturing.

Each stage carries risk, and most candidates never reach the market, which is why investors apply large discounts to early-stage programmes and tend to re-rate a company when a milestone is cleared.

TermWhat it means
sNDAA supplemental new drug application, used to seek approval for a new use of an already approved medicine
Priority ReviewA designation that aims for a faster FDA review timeline than standard review
PDUFA dateThe FDA’s target date for a decision on an application
Complete response letterThe FDA’s response when an application is not approved in its current form
Gross-to-netThe difference between a product’s list-price sales and the net revenue booked after rebates, discounts and other deductions
Peak revenue estimateA projection of the highest annual sales a product might reach, which is an estimate rather than a result

Knowing these terms makes the January 2027 ARIKAYCE decision, for example, much easier to follow: it is a PDUFA date for an sNDA that received Priority Review.

Insmed Stock News: Q3 2026 Results

Insmed reported its third-quarter results on 29 October 2026. Here are the main numbers, taken from the company’s filing:

MetricQ3 2026
Total revenue$524.4 million
BRINSUPRI revenue$400.1 million (up 29% on Q2)
ARIKAYCE revenue$124.4 million (up 9% year on year)
Total revenue growth, year on yearAbout 268%
Net lossAbout $100 million (EPS –$0.46)

Revenue beat analysts’ expectations, while the loss per share came in wider than forecast. Management raised the low end of its full-year 2026 guidance for both products, to $1.35–$1.40 billion for BRINSUPRI and $460–$470 million for ARIKAYCE.

BRINSUPRI: The Growth Engine

BRINSUPRI’s launch has been steep. The product generated roughly $145 million in its first full quarter on the market, then $309 million in Q2 2026 (up 49% on Q1) and $400 million in Q3. Q3 total revenue was also about 23% higher than Q2’s $425.5 million. A launch curve is not a straight line, though, and investors will watch whether growth continues at this pace, how the Japanese and European rollouts develop and how much revenue is lost to rebates and discounts (the company guides to gross-to-net deductions in the mid-to-high 20% range for BRINSUPRI).

ARIKAYCE and the January 2027 FDA Decision

In September 2026 the FDA accepted Insmed’s supplemental new drug application for ARIKAYCE in MAC lung disease as part of a combination regimen. The agency granted Priority Review and set a target action date of 28 January 2027. A label expansion could widen ARIKAYCE’s addressable patient population; a delay or an unfavourable decision would likely be treated by the market as a setback. This is one of the most closely watched dates for anyone following Insmed stock news.

TPIP and the Wider Pipeline

TPIP’s Phase 3 PALM-ILD study in PH-ILD began in the fourth quarter of 2025, and the company has planned further Phase 3 studies in pulmonary arterial hypertension, progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. Pipeline timelines can move, and trial results are binary events by nature, so each readout is a potential catalyst in either direction.

A Leadership Change Worth Noting

In October 2026 Insmed announced that its chief financial officer, Sara Bonstein, would step down on 30 October after nearly seven years in the role. The company reaffirmed its full-year guidance alongside the announcement. Executive changes do not necessarily alter a company’s trajectory, but they are a normal item on an investor’s watch list.

INSM Stock Valuation: Understanding Negative Earnings

Insmed is loss-making, so the usual price-to-earnings ratio does not work as a yardstick. Data providers show a negative forward earnings multiple for 2026, and a positive but far-off one for 2027. Investors in this part of the market more often look at:

  • Price-to-sales and enterprise value-to-sales: the Insmed shares trade at around 17 times trailing sales and around 14 times expected 2026 sales, according to market-data providers.
  • Revenue growth and trajectory: how quickly sales are climbing and whether guidance is being raised.
  • Cash and funding needs: how long existing resources can fund operations and whether new equity might be needed.
  • Pipeline value: the probability-weighted worth of programmes still in development.

Short interest is another sentiment gauge. Around 6.5% of the free float was sold short at the time of the latest data, which indicates a meaningful number of investors are betting on weakness, and it can add to volatility when news arrives. Insmed’s research and development spending is substantial: it was about $255 million in the fourth quarter of 2025 alone, which helps explain why the company remains unprofitable despite rapid sales growth.

INSM Stock Forecast: What Analysts Expect

Analyst coverage of Insmed Inc stock is positive overall. Roughly 24 analysts cover the shares, and the consensus rating is Buy to Strong Buy.

MeasureFigure
Average price targetAbout $194
Lowest target$158
Highest target$243
Implied move to average targetAbout +60% from $121.16
Implied move to lowest targetAbout +30%
Implied move to highest targetAbout +100%

Averages vary between data providers (some show slightly higher numbers than others), and targets are revised frequently, sometimes after a single data release. In November 2026, for instance, one large broker trimmed its target modestly while keeping its Buy rating. It helps to treat targets as a way of framing scenarios rather than as promises: analysts can and do get it wrong, and a target is only as good as the assumptions behind it.

Insmed Stock Price Prediction: Scenarios, Not Certainties

Nobody can reliably predict a biotech share price, and we do not attempt to here. A more useful approach to any Insmed stock price prediction is to map the factors that could push the shares in different directions, and the dates when they might matter:

Upcoming eventWhy it matters
FDA decision on ARIKAYCE label expansion (target 28 January 2027)Could widen the market for a product already generating over $450 million a year
Q4 and full-year 2026 results (expected around mid-February 2027, unconfirmed)A test of whether BRINSUPRI’s growth continues and whether guidance is met
BRINSUPRI launches in Japan and EuropeShows whether demand is spreading beyond the US
TPIP Phase 3 progressDetermines how much value the market assigns to the pipeline
Broader biotech and interest-rate sentimentGrowth stocks often swing with the wider market mood

Factors that could support the shares: continued BRINSUPRI growth, further guidance upgrades, a positive ARIKAYCE decision, strong trial progress and a recovering biotech sector.

Factors that could weigh on the shares: a slowdown in BRINSUPRI uptake, a regulatory delay or rejection, disappointing trial data, the need to raise capital on unfavourable terms, or a broader pull-back in growth stocks.

Is Insmed a Good Stock to Buy? Insmed Stock Buy or Sell Considerations

There is no universal answer to is Insmed a good stock to buy or to the Insmed stock buy or sell question, because the answer depends on you: your time horizon, how much volatility you can tolerate and how the shares fit within the rest of your portfolio. Questions that investors commonly ask themselves include:

  • What is my time horizon? Long-term investors may focus on peak revenue potential and pipeline value, while shorter-term traders are likelier to focus on catalysts such as the January FDA date.
  • How would I react to a 30% fall? The 52-week range ($90.39 to $212.75) shows how large swings can be. If a sharp decline would force a sale, the position may be too large.
  • Am I diversified? Concentrating in a single biotech name carries event risk that a basket of holdings does not.
  • Do I understand the product? Reading the company’s filings and the FDA decision timeline is a sensible starting point.
  • Is there a plan for both outcomes? Many traders decide in advance where they would take profits or cut losses.

This is general information, not a recommendation. It is worth seeking independent advice if you are unsure whether a stock like this suits your circumstances.

Cautions to Note Before Trading Insmed Shares

Every investment carries risk, and biotech carries a particular kind. These are the main precautions to take on board:

  • Clinical and regulatory outcomes are binary. Trial results and FDA decisions can move a share price sharply in a single session, in either direction.
  • The company is not yet profitable. Continued losses mean the business may need to raise capital in future, which could dilute existing shareholders.
  • Competition and reimbursement. New treatments, pricing pressure and changes to healthcare reimbursement can affect revenue forecasts.
  • Launch risk. Rapid early sales growth does not guarantee the pace will continue as the patient pool is reached.
  • Sentiment swings. Growth and biotech stocks can move with interest rates and risk appetite, regardless of company news.
  • Leverage magnifies outcomes. If you trade shares through CFDs, CFD trading carries a high level of risk and may not be suitable for everyone, and gaps around news events can lead to fills at prices different from those requested.

A Simple Checklist for Reading a Biotech Earnings Release

Quarterly results can look intimidating, but a handful of questions will tell you most of what you need. They work for Insmed and for any other commercial-stage biotech.

  1. Where is revenue coming from? Split total revenue by product. In Q3, BRINSUPRI contributed roughly three-quarters of Insmed’s total, which shows how much the story depends on one launch.
  2. Is growth accelerating or slowing? Compare sequential growth (quarter on quarter) as well as year-on-year growth, since a young product’s year-on-year figures can look very large for a while.
  3. Did guidance change? Raised guidance suggests management is seeing momentum; unchanged or lowered guidance deserves a closer look. Check whether the range was narrowed or the low end lifted.
  4. What happened to margins and deductions? Gross-to-net deductions, cost of product sales and selling expenses show how much of each sales dollar the company keeps.
  5. How big is the loss, and is it narrowing? Compare operating expenses, especially research and development, with revenue growth to see whether the business is moving toward profitability.
  6. What is the cash position? Cash and investments determine how long the company can fund operations without raising capital, and a new share issue can dilute existing holders.
  7. Which milestones are coming? Management usually lists upcoming regulatory dates, trial readouts and launches, and these are the events most likely to move the share price.
  8. Did anything unusual change? Leadership changes, new partnerships, legal matters and changes in the share count are all worth noting.

Going through this list after each report, and comparing the answers quarter to quarter, builds a much clearer picture than reacting to a single headline number or to the first move in the share price after the release.

How Traders Follow INSM Stock

Most people who follow INSM stock combine a few simple habits:

  1. Track primary sources. Company press releases, SEC filings (such as 8-Ks) and the FDA calendar are the most reliable places to find out about Insmed stock news first-hand.
  2. Watch volume and short interest. Unusual volume often accompanies significant news, and short interest shows how much bearish positioning there is.
  3. Mark the 52-week range. The $90.39 low and $212.75 high act as reference points for risk and reward.
  4. Plan around event dates. Earnings and regulatory dates are when volatility tends to cluster, and our guides to trading earnings season and using single-stock CFDs around results explain how traders approach them.
  5. Size positions sensibly. Our guide to effective stop loss strategies and volatility trading guide cover ways to manage risk in a fast-moving market.
  6. Practise first. A demo account is a low-pressure way to test an approach, and our paper trading guide shows how.

Traders who prefer not to own shares sometimes use CFDs, which let you speculate on price movements in either direction without owning the underlying stock. Our complete guide to CFD trading explains how they work, and our look at AI healthcare stocks as CFDs shows how healthcare names are typically traded on MetaTrader platforms.

Start Online CFD Trading with VT Markets Today

If you are ready to put your understanding of biotech earnings and clinical-catalyst volatility to work in live markets, VT Markets provides access to tools and platforms to help you get started. Trade on powerful platforms like MetaTrader 4 (MT4) and MetaTrader 5 (MT5), designed for speed, reliability, and advanced trading features — exactly what you need when earnings figures drop and financial markets move fast.

New to trading? Practise risk-free with a VT Markets demo account before committing to a live account — ideal for simulating reactions to major earnings and regulatory events across currency pairs, US indices, shares and commodities without financial risk.

Open your live account with VT Markets today and access secure, transparent, and competitive CFD trading across some of the world’s most popular markets.

Frequently Asked Questions About Insmed Stock

1. What is the Insmed share price today?

Insmed (INSM) closed at $121.16 on Friday 13 November 2026, up 2.62% on the day, with a 52-week range of $90.39 to $212.75. Markets were closed over the weekend, so check a live quote on your platform for the latest price, as it moves throughout each trading session.

2. Why is INSM stock down this year if revenue is growing so fast?

Share prices reflect expectations as well as results. Insmed’s revenue has grown rapidly, with Q3 2026 revenue up 268% on a year earlier, but the shares began 2026 near $177 and have fallen roughly 30% since, with sharp swings around clinical, regulatory and market news. Rapid growth can be priced in, and biotech shares are sensitive to broader market sentiment.

3. What is the INSM stock forecast from analysts?

Roughly 24 analysts cover the shares, and the consensus is Buy to Strong Buy. The average price target is about $194, with individual targets ranging from $158 to $243. Targets are opinions that change often, and they are not guarantees.

4. Is Insmed a good stock to buy?

It depends on your goals, time horizon and risk tolerance. Insmed has strong revenue growth and a promising pipeline, but it is not yet profitable and its shares can swing sharply on trial results and regulatory decisions. The next key date is the FDA’s target action date of 28 January 2027 for ARIKAYCE. This is general information, not advice, so consider seeking independent advice.

Back To Top
server

Hello there 👋

How can I help you?

We're here to help

Chat with us

Start a live conversation through...

  • Telegram
    hold On hold
  • Coming Soon...

Hello there 👋

How can I help you?

telegram

Scan the QR code with your smartphone to start a chat with us, or click here.

Don’t have the Telegram App or Desktop installed? Use Web Telegram instead.

QR code